Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 166

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1B
Chunk 166
---
    97.1
     
    Policy for Recoupment of Executive Incentive Compensation in the Event of an Accounting Restatement (Incorporated by reference to Exhibit 97.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 (File No. 001-40908) filed on March 21, 2024).

    101.INS
     
    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

    101.SCH
     
    Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

+ Indicates management contract or compensatory plan.

88

Item 16. Form 10-K Summary

None.

89

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

    MiNK Therapeutics, Inc.

    Date: March 18, 2025
     
    By:
    /s/ Jennifer S. Buell, Ph.D.

    Jennifer S. Buell, Ph.D.

    President, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

    Name
     
    Title
     
    Date

    /s/ Jennifer S. Buell, Ph.D.
     
    President, Chief Executive Officer and Director 
     
    March 18, 2025

    Jennifer S. Buell, Ph.D.
     
    (Principal Executive Officer)

    /s/ Christine M. Klaskin
     
    Treasurer (Principal Financial Officer and Principal 
     
    March 18, 2025

    Christine M. Klaskin
     
    Accounting Officer)

    /s/ Garo H. Armen, Ph.D.
     
    Chairman of the Board of Directors
     
    March 18, 2025

    Garo H. Armen, Ph.D.

    /s/ Peter Behner
     
    Director
     
    March 18, 2025

    Peter